Detalhe da pesquisa
1.
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.
Ann Intern Med
; 176(1): 59-66, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36469914
2.
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Kidney Int
; 104(6): 1219-1226, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657768
3.
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
Cardiovasc Diabetol
; 22(1): 126, 2023 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37244998
4.
The effect of lifestyle intervention on cardiometabolic risk factors in mental health rehabilitation hostel residents at-risk: a cluster-randomized controlled 15-month trial.
Int J Obes (Lond)
; 46(5): 926-934, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35022545
5.
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults.
Cardiovasc Diabetol
; 21(1): 104, 2022 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35689214
6.
Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A narrative review and proposed clinical approach.
Diabetes Obes Metab
; 24(6): 969-982, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35212443
7.
α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4,5-bisphosphate.
J Biol Chem
; 295(52): 18076-18090, 2020 12 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33087443
8.
From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
Cardiovasc Diabetol
; 20(1): 92, 2021 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33910583
9.
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
Cardiovasc Diabetol
; 20(1): 169, 2021 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407822
10.
[IMPROVEMENT OF RENAL OUTCOMES WITH SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS].
Harefuah
; 160(10): 671-678, 2021 10.
Artigo
em Hebraico
| MEDLINE | ID: mdl-34689438
11.
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
Ann Intern Med
; 176(7): eL230070, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459628
12.
Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.
Diabetes Obes Metab
; 25(10): 3054-3058, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37385956
13.
Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty.
J Gerontol A Biol Sci Med Sci
; 79(2)2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37527836
14.
Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.
Clin Kidney J
; 16(4): 701-710, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37007688
15.
Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.
Clin J Am Soc Nephrol
; 18(9): 1153-1162, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37382938
16.
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.
NEJM Evid
; 2(6): EVIDoa2300049, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38320128
17.
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
Lancet Diabetes Endocrinol
; 11(4): 233-241, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878239
18.
Loss of Corticostriatal Mu-Opioid Receptors in α-Synuclein Transgenic Mouse Brains.
Life (Basel)
; 12(1)2022 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35054456
19.
Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers.
Front Pharmacol
; 13: 786767, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35496307
20.
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.
Diabetes Care
; 45(11): 2644-2652, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36134918